argenx NV ADR (ARGX)vsEffector Therapeutics Inc (EFTR)
ARGX
argenx NV ADR
$984.39
+0.04%
HEALTHCARE · Cap: $64.63B
EFTR
Effector Therapeutics Inc
$0.00
0.00%
HEALTHCARE · Cap: $2,352
Smart Verdict
WallStSmart Research — data-driven comparison
argenx NV ADR generates 787377% more annual revenue ($5.32B vs $675,000). ARGX leads profitability with a 32.3% profit margin vs 0.0%. ARGX earns a higher WallStSmart Score of 73/100 (B).
ARGX
Strong Buy73
out of 100
Grade: B
EFTR
Avoid34
out of 100
Grade: F
Intrinsic Value Comparison
Multi-model valuation · Graham Formula
Margin of Safety
+64.8%
Fair Value
$2371.09
Current Price
$984.39
$1386.70 discount
Intrinsic value data unavailable for EFTR.
Key Strengths & Concerns
Side-by-side fundamental analysis
Key Strengths
Every $100 of equity generates 31 in profit
Keeps 32 of every $100 in revenue as profit
Strong operational efficiency at 32.0%
Revenue surging 59.3% year-over-year
Earnings expanding 95.2% YoY
Conservative balance sheet, low leverage
Reasonable price relative to book value
Revenue surging 117.0% year-over-year
Areas to Watch
Premium valuation, high expectations priced in
Weak financial health signals
Trading at 183.0x book value
0.0% earnings growth
Smaller company, higher risk/reward
0.0% margin — thin
Operating margin of 0.0%
Comparative Analysis Report
WallStSmart ResearchBull Case : ARGX
The strongest argument for ARGX centers on Return on Equity, Profit Margin, Operating Margin. Profitability is solid with margins at 32.3% and operating margin at 32.0%. Revenue growth of 59.3% demonstrates continued momentum.
Bull Case : EFTR
The strongest argument for EFTR centers on Price/Book, Revenue Growth. Revenue growth of 117.0% demonstrates continued momentum.
Bear Case : ARGX
The primary concerns for ARGX are P/E Ratio, Piotroski F-Score, Price/Book.
Bear Case : EFTR
The primary concerns for EFTR are EPS Growth, Market Cap, Profit Margin.
Key Dynamics to Monitor
ARGX profiles as a growth stock while EFTR is a hypergrowth play — different risk/reward profiles.
EFTR carries more volatility with a beta of 2.42 — expect wider price swings.
EFTR is growing revenue faster at 117.0% — sustainability is the question.
ARGX generates stronger free cash flow (749M), providing more financial flexibility.
Bottom Line
ARGX scores higher overall (73/100 vs 34/100), backed by strong 32.3% margins and 59.3% revenue growth. Both earn "Strong Buy" and "Avoid" ratings respectively — the choice depends on your investment horizon and risk tolerance.
This analysis is generated from publicly available financial data. Not financial advice.
argenx NV ADR
HEALTHCARE · BIOTECHNOLOGY · USA
argenx SE, a clinical-phase biotechnology company, focuses on the development of antibody-based therapies for the treatment of autoimmune diseases, hematology and cancer. The company is headquartered in Breda, the Netherlands.
Effector Therapeutics Inc
HEALTHCARE · BIOTECHNOLOGY · USA
Effector Therapeutics Inc (EFTR) is a clinical-stage biopharmaceutical company dedicated to redefining cancer treatment through the innovative modulation of RNA translation to selectively target tumor growth. With a robust pipeline of small molecule therapies, the company is strategically positioned to address critical unmet needs within oncology. Focused on advancing precision medicine, Effector Therapeutics aims to improve treatment outcomes and enhance the quality of life for cancer patients, all while navigating the dynamic landscape of biotechnology innovation.
Compare with Other BIOTECHNOLOGY Stocks
Want to dig deeper into these stocks?